SEC Form 4 · accession 0001193125-26-276054
Cullinan Therapeutics, Inc. · CGEM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mittie Doyle
Director
Period of report
Jun 16, 2026
Accepted (ET)
Jun 18, 2026 · 5:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001789972
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $13.55 | Jun 16, 2026 | A | 21,781 | A | — | Jun 16, 2026 | Common Stock | 21,781 | 21,781 | D |
Explanation of responses
- F1The option represents a right to purchase a total of 21,781 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.